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The widespread use of pediatric diphtheria, tetanus, and
pertussis vaccines has led to a dramatic decline in pertus-
sis. However, a resurgence of pertussis has recently been
observed, particularly among adolescents and adults,
now considered important sources of infections. The ad-
dition of an acellular pertussis component to the CDC-
recommended diphtheria and tetanus adult booster vac-
cine could reduce the occurrence of pertussis. Although
policy-makers will base their decisions on epidemiologi-
cal, clinical, and ethical grounds, they may also require
evidence of the economic value of this added component
before formulating a final immunization recommendation.
OBJECTIVES: To provide a preliminary assessment of
the economic value of vaccinating all new parents (or
guardians) at the time of birth of their first child. METH-
ODS: A literature-based decision analysis was developed
to estimate the clinical and epidemiological costs and
benefits of this vaccination strategy. The model projects
the number of—and the direct and indirect cost savings
associated with—mild, hospitalized, and fatal clinical
pertussis cases prevented in vaccinated adults and in non-
vaccinated children (due to herd immunity). RESULTS:
Our analysis suggests that such a vaccination strategy
could prevent 12,000 to 28,000, mostly adult, infections
and about 1000 hospitalizations annually. The results
also indicate that vaccination may be cost-effective, with
a cost per infection avoided ranging between $632 and
$1318. CONCLUSIONS: The results of this analysis sug-
gest that adult booster pertussis vaccination provides
substantial economic and clinical benefits. Policy makers
should not exclude adults from their recommendation
considerations until more definitive epidemiological and
economic data become available.
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Studies have shown that combination interferonribavirin
is a cost-effective treatment for Hepatitis C from a soci-
etal perspective. Safety-net hospitals are currently faced
with the prospect of paying for an expensive treatment
for their many patients who are unable to pay. OBJEC-
TIVES: Examine the cost-effectiveness of alternative
treatment strategies for Hepatitis C as it affects the
safety-net hospital. METHODS: A Markov decision ana-
lytic model was constructed, using a reference case of a
45 year-old male with Hepatitis C, but without cirrhosis.
The perspective adopted was a safety-net hospital. Two
populations were examined: uninsured, and insured, but
without coverage for combination interferonribavirin.
Two strategies were considered: (1) CMB/G—Combina-
tion therapy for 6 or 12 months depending on virus gen-
otype, and (2) IFN/CMB, a cost saving strategy that be-
gins with 12 months of interferon monotherapy, followed
by 6 months of combination therapy for interferon re-
lapsers. Data came from prior publications. RESULTS:
In the uninsured group, CMB/G cost an additional $10,700
per patient, with an incremental cost-effectiveness ra-
tio(ICER) of $9600/QALY. Considering varying degrees
of aggressive disease (i.e., progression to cirrhosis), the
ICERs ranged from $6000/QALY–$12,100/QALY. In
the underinsured group, CMB/G was associated with an
additional cost of $13,100 per patient, with an ICER of
$11,700/QALY. For very aggressive disease, the ICER
for CMB/G dropped to $6900/QALY. For mild disease,
the ICER for CMB/G rose to $15,100/QALY. CON-
CLUSIONS: Although ICERs would appear to be cost-
effective from a societal perspective, this is less clear for
hospitals. Cost-saving strategies, such as starting with in-
terferon, and only giving combination therapy to relaps-
ers may be a necessary option for the safety-net hospital
struggling to find the funds to pay for treatment for their
large, indigent population.
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Antibiotics help reduce the economic burden of 600,000
annual hospitalizations and added outpatient visits and
days missed from work, school, and other activities due
to community-acquired pneumonia (CAP). OBJEC-
TIVES: To compare costs, outpatient visits, and 28-day
outcomes with gatifloxacin versus ceftriaxone among
adult patients with CAP. METHODS: Data were col-
lected on health care resource use from 287 inpatients
with CAP randomized to receive initial IV therapy with
either gatifloxacin alone (GAT) or ceftriaxone /
erythromycin (CEF). After at least two days of IV ther-
apy, patients could be switched to oral therapy with GAT
(GAT arm) or clarithromycin (CEF arm) at the treating
physician’s discretion. Total costs, which include medica-
tion, outpatient, and hospital costs, and the number of
outpatient visits and days missed from work, school, and
other activities were calculated. The analysis was limited
to clinically evaluable patients. RESULTS: A total of 205
patients were clinically evaluable (99 GAT, 106 CEF).
The mean total cost for the GAT arm was less than the
CEF arm ($5665 vs. $6469; P  0.149). The mean total
cost for patients admitted to the ICU was lower for pa-
tients.
